Understanding how CAR T-cells work in fighting cancer
Mechanisms regulating chimeric antigen receptor T-cell activity in cancer
['FUNDING_CAREER'] · WASHINGTON UNIVERSITY · NIH-10676212
This study is looking into how CAR T-cells, a special type of treatment for certain cancers, work and why they might not help everyone, with the goal of finding ways to make them more effective for patients with cancers like non-Hodgkin lymphoma and acute lymphoblastic leukemia.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10676212 on ClinicalTrials.gov |
What this research studies
This research investigates the molecular mechanisms that regulate the activity of chimeric antigen receptor (CAR) T-cells, which are a type of immunotherapy used to treat certain cancers. The study aims to identify why some patients do not respond to CAR T-cell therapy and how these cells can be made more effective. By analyzing samples from clinical trials and using mouse models, researchers will explore how specific proteins and signaling pathways affect the ability of CAR T-cells to persist and attack tumors. This work could lead to improved treatments for patients with cancers like non-Hodgkin lymphoma and acute lymphoblastic leukemia.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with non-Hodgkin lymphoma or acute lymphoblastic leukemia who are undergoing or have undergone CAR T-cell therapy.
Not a fit: Patients with cancers not treated by CAR T-cell therapy or those who are not eligible for this type of treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance the effectiveness of CAR T-cell therapy, leading to better outcomes for cancer patients.
How similar studies have performed: Previous research has shown promise in enhancing CAR T-cell therapies, but this specific investigation into death receptors and immune memory formation is a novel approach.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SINGH, NATHAN — WASHINGTON UNIVERSITY
- Study coordinator: SINGH, NATHAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer